New sudan ebola vaccine moves to phase 2 trial in healthy adults
NCT ID NCT06803342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental vaccine against Sudan ebolavirus in 200 healthy adults aged 18 to 70. The vaccine uses a harmless chimpanzee virus to deliver protection. Researchers will check for side effects and measure immune responses 29 days after vaccination. The goal is to see if the vaccine is safe and triggers a strong immune defense.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA SUDAN VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Optimal Research; LLC
Melbourne, Florida, 32934, United States
-
Synexus Clinical Research US, Inc.
Phoenix, Arizona, 85020, United States
-
Synexus Clinical Research US, Inc.
Chicago, Illinois, 60602, United States
-
Synexus Clinical Research US, Inc.
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.